New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:53 EDTCBMGCellular Biomedicine releases positive ReJoin Phase I/IIa six-month data
Cellular Biomedicine released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin human adipose-derived mesenchymal precursor cell, or haMPC, therapy for Knee Osteoarthritis, or KOA. The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. The primary endpoints for this trial were safety and knee-related pain, stiffness and function measured using the Western Ontario and McMaster Universities osteoarthritis index questionnaire. The secondary endpoints were cartilage repair at six months, defined through the volume of the repair tissue measured with quantitative magnetic resonance imaging as well as NRS-11, SF-36 and KSCRS scores.
News For CBMG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
08:48 EDTCBMGCellular Biomedicine reports Q4 EPS (36c), one estimate (32c)
Reports Q4 revenue $564,377, one estimate $200,000.
March 25, 2015
10:00 EDTCBMGCellular Biomedicine announces phase I results from CAR-T program
Subscribe for More Information
09:10 EDTCBMGCellular Biomedicine announces interim results from ReJoin Phase IIb trial
Cellular Biomedicine Group announced interim 24-week clinical data from the Phase IIb trial of its ReJoin human adipose-derived mesenchymal progenitor cell, or haMPC, therapy for Knee Osteoarthritis, or KOA. The 24-week interim data shows the primary and secondary endpoints of ReJoin therapy group have all improved significantly compared to their baseline, which has confirmed the Phase IIa report, although only the change of WOMAC, the primary endpoint, is significantly higher than that of the ARTZŅ control group. A trend of improvement of the secondary endpoints, including cartilage MRI quantification, is observable at the 24th week. The company expects the final results to be available at the end of 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use